Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy

Journal of Clinical Oncology

Volumn 24, Issue 5, 2006, Pages 823-834

  Goldenberg, David M ^a   Sharkey, Robert M ^b   Paganelli, Giovanni ^b   Barbet, Jacques ^b   Chatal, Jean François ^b  

^a GARDEN STATE CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN Y 90; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; HAPTEN I 131; IMMUNOGLOBULIN G CD20 ANTIBODY Y 90; IMMUNOGLOBULIN G TUMOR ASSOCIATED GLYCOPROTEIN 72 ANTIBODY Y 90; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; CANCER ANTIBODY; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; HAPTEN; STREPTAVIDIN;

BINDING SITE; BLOOD TOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNODETECTION; ISOTOPE LABELING; LUNG SMALL CELL CANCER; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; IMMUNOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; RADIOIMMUNOASSAY; SCINTISCANNING; THYROID TUMOR;

ANTIBODIES, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; GLIOMA; HAPTENS; HUMANS; INDICATORS AND REAGENTS; LUNG NEOPLASMS; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; STREPTAVIDIN; THYROID NEOPLASMS;

EID: 33644869654     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.8471     Document Type: Review

References (104)

1. Wilder RB, DeNardo GL, DeNardo SJ: Radioimmunotherapy: Recent results and future directions. J Clin Oncol 14:1383-1400, 1996
2. Sharkey RM, Goldenberg DM: Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 46:115S-127S, 2005
3. Waldmann TA: Immunotherapy: Past, present and future. Nature Med 9:269-277, 2003
4. Casadavall A: Antibody-based therapies as anti-infective agents. Expert Opin Investig Drugs 7:307-321, 1998
5. Goldenberg DM: Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43:693-713, 2002
6. Schubiger PA, Alberto R, Smith A: Vehicles, chelators, and radionuclides: Choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconj Chem 7:165-179, 1996
7. Milenic DE, Brady ED, Brechbiel MW: Antibody-targeted radiation cancer therapy. Nature Rev Drug Discov 3:488-498, 2004
8. Jhanwar YS, Divgi C: Current status of therapy of solid tumors. J Nucl Med 46:141S-150S, 2005
9. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463, 2002
10. Davis TA, Kaminski MS, Leonard JP, et al: The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 10:7792-7798, 2004
11. Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-3928, 2001
12. Sharkey RM, Burton J, Goldenberg DM: Radioimmunotherapy of non-Hodgkin's lymphoma: A critical appraisal. Expert Rev Clin Immunol 1:47-62, 2005
13. Schlumberger M, Challeton C, De Vathaire F, et al: Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37:598-605, 1996
14. 131I-labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results. J Clin Oncol 23:6763-6770, 2005
15. Zalutsky MR: Current status of therapy of solid tumors: Brain tumor therapy. J Nucl Med 46:151S-156S, 2005
16. 90Y-biotin? Gynecol Oncol 93:691-698, 2004
17. McQuarrie S, Mercer J, Syme A, et al: Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. J Pharm Sci 7:29-34, 2005
18. 90yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 8:2806-2811, 2002
19. Reardan DT, Meares CF, Goodwin DA, et al: Antibodies against metal chelates. Nature 316:265-268, 1985
20. Goodwin DA, Meares CF, McCall MJ, et al: Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 29:226-234, 1988
21. Goodwin DA, Meares CF: Advances in pre-targeting biotechnology. Biotechnol Adv 19:435-450, 2001
22. Chang CH, Sharkey RM, Rossi EA, et al: Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther 1:553-563, 2002
23. Boerman OC, van Schaijk FG, Oyen WJ, et al: Pretargeted radioimmunotherapy of cancer: Progress step by step. J Nucl Med 44:400-441, 2003
24. Le Doussal JM, Martin M, Gautherot E, et al: In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 30:1358-1366, 1989
25. 90Y radioimmunotherapy in a mouse xenograft model. J Immunother 16:158, 1994 (abstr 41)
26. Moro M, Pelagi M, Fulci G, et al: Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha. Cancer Res 57:1922-1928, 1997
27. Paganelli G, Pervez S, Siccardi AG, et al: Intraperitoneal radiolocalization of tumors pre-targeted by biotinylated monoclonal antibodies. Int J Cancer 45:1184-1189, 1990
28. Chinol M, De Cobelli O, Trifirò G, et al: Localization of avidin in superficial bladder cancer: A potentially new approach for radionuclide therapy. Eur Urol 44:556-559, 2003
29. Yao Z, Zhang M, Kobayashi H, et al: Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase. J Nucl Med 36:837-841, 1995
30. Saga T, Weinstein JN, Jeong JM, et al: Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled streptavidin. Cancer Res 54:2160-2165, 1994
31. He J, Liu G, Gupta S, et al: Amplification targeting: A modified pretargeting approach with potential for signal amplification-proof of a concept. J Nucl Med 45:1087-1095, 2004
32. Bagshawe KD, Sharma SK, Begent RH: Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin Biol Ther 4:1777-1789, 2004
33. Rossi EA, Sharkey RM, McBride W, et al: Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res 9:3886s-3896s, 2003
34. Rossi EA, Chang C-H, Losman MJ, et al: Pretargeting of CEA-expressing cancer with a trivalent fusion protein produced in myeloma cells. Clin Cancer Res 11:7122s-7129s, 2005
35. Hnatowich DJ, Virzi F, Rusckowski M: Investigations of avidin and biotin for imaging applications. J Nucl Med 28:1294-1302, 1987
36. Axworthy DB, Reno JM, Hylarides MD, et al: Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 97:1802-1807, 2000
37. Forero A, Weiden PL, Vose JM, et al: Phase I trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 104:227-236, 2004
38. Shen S, Forero A, Lobuglio AF, et al: Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med 46:642-651, 2005
39. Cheung NK, Modak S, Lin Y, et al: Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J Nucl Med 45:867-877, 2004
40. Sato N, Hassin R, Axworthy DB, et al: Pre-targeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J Nucl Med 46:1201-1209, 2005
41. Chauhan J, Dakshinamurti KL: Purification and characterization of human serum biotinidase. J Biol Chem 261:4268-4275, 1986
42. Karacay H, Sharkey RM, Govindan SV, et al: Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer: Reagent development. Bioconj Chem 8:585-594,1997
43. Goodwin DA, Meares CF, Osen M: Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system. J Nucl Med 39:1813-1818, 1998
44. Sabatino G, Chinol M, Paganelli G, et al: A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors. J Med Chem 46:3170-3173, 2003
45. Paganelli G, Magnani P, Zito F, et al: Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 51:5960-5966, 1991
46. Goodwin DA, Meares CF, McTigue M, et al: Pretargeted immunoscintigraphy: Effect of hapten valency on murine tumor uptake. J Nucl Med 33: 2006-2013, 1992
47. Boerman OC, Kranenborg MH, Oosterwijk E, et al: Pretargeting of renal cell carcinoma: Improved tumor targeting with a bivalent chelate. Cancer Res 59:4400-4405, 1999
48. Karacay H, Sharkey RM, McBride WJ, et al: Pretargeting for cancer radioimmunotherapy with bispecific antibodies: Role of the bispecific antibody's valency for the tumor target antigen. Bioconjug Chem 13:1054-1070, 2002
49. Sharkey RM, Karacay H, Richel H, et al: Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res 9: 3897s-3913s, 2003
50. Sharkey RM, Cardillo TM, Rossi EA, et al: Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nature Med 11:1250-1255, 2005
51. Behr TM, Memtsoudis S, Sharkey RM, et al: Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and antitumor efficacy. Int J Cancer 77:787-795, 1998
52. Sharkey RM, Karacay H, Cardillo TM, et al: Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 11:7109s-7121s, 2005
53. Paganelli G, Chinol M: Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 30:773-776, 2003
54. Goldenberg DM, Chang CH, Sharkey RM, et al: Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 30:777-780, 2003
55. 90Y-DOTA-biotin. J Nucl Med 41:131-140, 2000
56. Paganelli G, Grana C, Chinol M, et al: Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 26: 348-357, 1999
57. Weiden PL, Breitz HB, Press O, et al: Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results. Cancer Biother Radiopharm 15:15-29, 2000
58. Le Doussal JM, Chetanneau A, Gruaz-Guyon A, et al: Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: Pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med 34:1662-1671, 1993
59. Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, et al: Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x antihapten bispecific antibody-mediated pretargeting of iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res 9:3973s-3981s, 2003
60. Goldenberg DM, Juweid M, Dunn RM, et al: Cancer imaging with radiolabeled antibodies: New advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan, and prospects for therapy. J Nucl Med Technol 25:18-23, 1997
61. Kalofonos HP, Rusckowski M, Siebecker DA, et al: Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: Preliminary communication. J Nucl Med 31:1791-1796, 1990
62. Stickney DR, Anderson LD, Slater JB, et al: Bifunctional antibody: A binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res 51:6650-6655, 1991
63. Chetanneau A, Barbet J, Peltier P, et al: Pretargetted imaging of colorectal cancer recurrences using an 111In-labelled bivalent hapten and a bispecific antibody conjugate. Nucl Med Commun 15:972-980, 1994
64. Barbet J, Peltier P, Bardet S, et al: Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med 39:1172-1178, 1998
65. Vuillez JP, Moro D, Brichon PY, et al: Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 38:507-511, 1997
66. Magnani P, Paganelli G, Modorati G, et al: Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med 37:967-971, 1996
67. Kelloff GJ, Hoffman JM, Johnson B, et al: Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11:2785-2808, 2005
68. Schuhmacher J, Kaul S, Klivenyi G, et al: Immunoscintigraphy with positron emission tomography: Gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res 61:3712-3717, 2001
69. 64Cu for tumor imaging and therapy. J Nucl Med 44:1284-1292, 2003
70. 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. J Nucl Med 45: 30-39, 2004
71. 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm 14:381-395, 1999
72. Breitz HB, Fisher DR, Wessels BW: Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody. J Nucl Med 39:1746-1751, 1998
73. Knox SJ, Goris ML, Tempero M, et al: Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 6:406-414, 2000
74. Press OW, Corcoran M, Subbiah K, et al: A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 98:2535-2543, 2001
75. Sharkey RM, Karacay H, Chang CH, et al: Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 19: 1064-1069, 2005
76. 90Y-biotin dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med 26:110-120, 1999
77. Grana C, Chinol M, Robertson C, et al: Pre-targeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study. Br J Cancer 86:207-212, 2002
78. Paganelli G, Orecchia R, Jereczek-Fossa B, et al: Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. Eur J Nucl Med 25: 1336-1339, 1998
79. Gautherot E, Le Doussal JM, Bouhou J, et al: Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. J Nucl Med 39:1937-1943, 1998
80. Gautherot E, Bouhou J, Le Doussal J-M, et al: Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten. Cancer 80:2618-2623, 1997
81. 131I- labeled bivalent hapten. J Nucl Med 41:480-487, 2000
82. 2 and pretargeted bivalent hapten and evaluation of repeated injections. Clin Cancer Res 5:3183s-3189s, 1999
83. Gruaz-Guyon A, Janevik-Ivanovska E, Raguin O, et al: Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy. Q J Nucl Med 45:201-206, 2001
84. Karacay H, Brard P-Y, Sharkey RM, et al: Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 11:7879-7885, 2005
85. Bardies M, Bardet S, Faivre-Chauvet A, et al: Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J Nucl Med 37:1853-1859, 1996
86. Barbet J, Campion L, Kraeber-Bodere F, et al: Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077-6084, 2005
87. Vuillez JP, Kraeber-Bodere F, Moro D, et al: Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anticarcinoembryonic antigen/anti-diethylenetriamine-pentaacetic acid (DTPA) antibody and iodine-131 di-DTPA hapten: Results of a phase I/II trial. Clin Cancer Res 5:3259s-3267s, 1999
88. Kraeber-Bodere F, Bardet S, Hoefnagel CA, et al: Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: Preliminary results of a phase I/II clinical trial. Clin Cancer Res 5:3190s-3198s, 1999
89. Mirallie E, Vuillez JP, Bardet S, et al: High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 90:779-788, 2005
90. Chatal J-F, Campion L, Kraeber-Bodere F, et al: Survival improvement in medullary thyroid carcinoma patients receiving pretargeted CEA radioimmunotherapy. J Clin Oncol (in press)
91. Kraeber-Bodere F, Rousseau C, Bodet-Milin C, et al: Targeting, toxicity and efficacy of two-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and iodine-131-labeled bivalent hapten in a phase-I optimization clinical trial. J Nucl Med (in press)
92. DeNardo SJ, Richman CM, Kukis DL, et al: Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: Development of a clinical protocol. Anticancer Res 18:4011-4018, 1998
93. Clarke K, Lee FT, Brechbiel MW, et al: Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: Enhanced activity when combined with taxol chemotherapy. Clin Cancer Res 6:3621-3628, 2000
94. 90yttrium-DOTA-peptide-ChL6. Prostate 5027-5037, 2002
95. Blumenthal RD, Leone E, Goldenberg DM, et al: An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: Effects of p53 expression. Int J Cancer 108: 293-300, 2004
96. 90Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res 9:3929S-3937S, 2003
97. Press OW, Unger JM, Braziel RM, et al: A phase II trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102:1606-1612, 2003
98. Vose JM, Bierman PJ, Enke C, et al: Phase I trialofiodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 23:461-467, 2005
99. Winter JN: Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. Clin Lymphoma 5:S22-S26, 2004
100. 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 46:620-633, 2005
101. 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 9:5842-5852, 2003
102. Graves SS, Dearstyne E, Lin Y, et al: Combination therapy with pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res 9:3712-3721, 2003
103. Kraeber-Bodere F, Sai-Maurel C, Campion L, et al: Enhanced antitumor activity of combined pre-targeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther 1:267-274, 2002
104. 90Y-biotin radioimmunotherapy and temozolomide. Q J Nucl Med Mol Imaging 48:220-228, 2004